睾酮替代治疗对老年性腺功能减退男性非酒精性脂肪性肝病的影响
本文为睾酮试验(T Trials)的二次数据分析,纳入479例总睾酮<275 ng/dL的老年性腺功能减退男性。与安慰剂组相比,睾酮治疗12个月未显著改善三项临床肝脏脂肪评分及肝脏CT所评估的肝脂肪变;作者认为需更长期治疗及以其他NAFLD诊断方式为主要结局的未来研究。
要点
- 睾酮治疗12个月未显著改善三项临床肝脏脂肪评分。
- 肝脏CT的Hounsfield单位及肝脾比在两组间无显著差异。
- 作者认为需更长期治疗及以其他NAFLD诊断方式为主要结局的研究。
核心结论
- 在老年性腺功能减退男性中,睾酮治疗12个月与安慰剂相比未显示非酒精性脂肪性肝病改善,评估依据为3项临床评分和肝脏CT肝脂肪变评估。
- 作者认为需开展治疗时间更长、并以其他NAFLD诊断方式为主要结局的未来研究。
研究设计与样本
- 睾酮试验(T Trials)的二次数据分析,纳入479例总睾酮<275 ng/dL的老年性腺功能减退男性。
- 在基线及治疗12个月后评估3项临床肝脏脂肪评分及肝脏CT Hounsfield单位与肝脾比。
主要发现
- 246例接受睾酮治疗与233例接受安慰剂治疗12个月者相比,脂质蓄积产物指数的变化无统计学显著差异(P = .98)。
- 肝脂肪变指数变化无统计学显著差异(P = .67)。
- 非酒精性脂肪性肝病-代谢综合征评分变化无统计学显著差异(P = .52)。
- 肝脏CT Hounsfield单位变化无统计学显著差异(P = .24;睾酮组n = 71,安慰剂组n = 69)。
- 肝脾比变化无统计学显著差异(P = .74;睾酮组n = 55,安慰剂组n = 62)。
局限性
- 作者指出需开展治疗时间更长、并以其他NAFLD诊断方式为主要结局的未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Male hypogonadism is associated with visceral obesity and the metabolic syndrome: factors important for the development of nonalcoholic fatty liver disease (NAFLD). The Testosterone Trials (The T Trials) showed testosterone (T) treatment compared with placebo in older hypogonadal men was associated with decreases in cholesterol and insulin levels suggesting that T treatment may improve NAFLD. OBJECTIVE: Compare effects of T vs placebo treatment on NAFLD scores and liver scans in elderly hypogonadal men. METHODS: Secondary data analyses from 479 older hypogonadal men with total T < 275 ng/dL from The T Trials were performed. Three clinical liver fat scores-lipid accumulation product index, hepatic steatosis index, nonalcoholic fatty liver disease-metabolic syndrome score-and liver computed tomography (CT) Hounsfield units and liver to spleen ratio were evaluated at baseline and 12 months after treatment. RESULTS: There were no statistically significant differences of change in lipid accumulation product index (P = .98), hepatic steatosis index (P = .67), and nonalcoholic fatty liver disease-metabolic syndrome (P = .52) in 246 men treated with T compared with 233 treated with placebo for 12 months. Liver CT showed no statistically significant difference of change in Hounsfield units (P = .24; n = 71 for T, n = 69 for placebo) and liver to spleen ratio (P = .74; n = 55 for T, n = 62 for placebo) between the 2 groups. CONCLUSIONS: Our study did not show improvement of NAFLD in older hypogonadal men after 12 months of T vs placebo treatment, as assessed by 3 clinical scores and liver CT for hepatic steatosis. Future studies with longer treatment duration and additional NAFLD diagnostic modalities as primary outcome are warranted.
引用
- Lee HS, Han SH, Swerdloff R, et al. The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men. J Clin Endocrinol Metab. 2024. PMID: 37656011. doi:10.1210/clinem/dgad511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。